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In recent years evidence has accumulated 
that genes involved in circadian clock control 
play a role as tumor suppressors. Strong evi-
dence has been presented by Broadberry and 
colleagues who published an article about dis-
rupted circadian clocks in breast cancer 
(Broadberry et al., 2018). The authors studied 
primary mammary epithelial cells from nor-
mal breast tissue and epithelial cells from 
breast carcinomas of the same patients. They 
transduced the cells with the luciferase clock 
reporter PER2:Luc, which is known to show 
a robust ~24 h rhythm in normal epithelial 
cells (Yang et al., 2017). The normal epithe-
lial breast cells showed the expected cycling. 
However, epithelial cells from the cancer tis-
sue of the same individuals showed a dis-
rupted rhythm with a much lower amplitude 
(Broadberry et al., 2018). This study confirms 
previous studies presenting evidence for a tu-
mor suppressor role of the circadian clock 
(Gery and Koeffler, 2010; Grundy et al., 
2013; Fu and Lee, 2003; Mormont and Lévi, 
1997; Filipski et al., 2002). Loss of clock 
genes has been shown to be associated with 
worse prognosis in breast cancer (Cadenas et 
al., 2014). Coordinated co-expression of 
clock genes (e.g. PER2-PER3 and CRY2-
PER3) is maintained in estrogen receptor pos-
itive and HER2 negative carcinomas but is 
compromised in more aggressive tumors (Ca-
denas et al., 2014). Genes relevant for pro-
gression of breast carcinomas have been 
shown to be associated with proliferation 
(Siggelkow et al., 2012), the cellular and hu-
moral immune system (Schmidt et al., 2008, 
2012; Heimes et al., 2017a, b; Lohr et al., 
2013; Godoy et al., 2014), anti-oxidative and 
anti-apoptotic factors (Hellwig et al., 2016; 
Cadenas et al., 2010) and altered metabolism 
(Cadenas et al., 2019; Marchan et al., 2017; 
Stewart et al., 2012). Although the loss of cir-
cadian clock gene expression and its associa-
tion with tumor prognosis has clearly been 
shown, the mechanisms of their tumor sup-
pressive effect still need to be elucidated.  
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